Skip navigation

Login / Register

0

0113 202 9799

Attend2 COPD

COPD is the second most common cause of emergency admissions to hospital.

Attend2 COPD is underpinned by national and international guidelines (including the GOLD report and NICE NG115) and is used to identify patients who may benefit from a review of their current management strategy.

The service can be used to support the management of patients with COPD, highlighting patients missing key records such as annual reviews, symptom scores (MRC or CAT), exacerbation counts and pulmonary rehab status, prioritising them based on the burden of illness.

Attend2 COPD stratifies COPD patients, taking into account a patient’s current level of symptoms & exacerbations, treatments and co-morbidities as well as other risk factors (e.g. smoking status). Stratifying patients according to the level of clinical need allows practices to more effectively plan and prioritise their workload to optimise patient care.

Action plans can then be drafted, delivering the associated clinical work and measuring outcomes as part of an effective QI cycle in COPD and working to manage the backlog of care as a result of COVID-19.

Attend2 COPD

Need some help? Get in touch

Attend2 COPD

Recommended

Attend2 COPD with consultation   £1,742 + VAT

  • Attend2 platform with user guide to help understand the tool and how best to implement it within the practice
  • Full 1-day tour and training session on the Attend2 tool delivered by a Clinical Pharmacist. This session will also function as a consultancy session, working through patients and immediately delivering clinical outcomes.
  • Attend2 refresh.  An updated Attend2 tool housing refreshed data to help deliver continuing clinical outcomes.

Attend2 COPD   £1,025 + VAT

  • Attend2 platform with user guide to help understand the tool and how best to implement it within the practice

Refresh of Attend2 COPD Data   £200 + VAT per refresh

An updated Attend2 tool housing refreshed data to help deliver continuing clinical outcomes.